Foghorn Therapeutics
Price & Volume
Stats
See more52W Range | $2.94-$10.25 |
Market Cap | $248.5M |
Shares Short | 1M |
Financials
See moreRevenue (12 Mos) | $22.6M |
Revenue Growth (YoY) | -50.5% |
Gross Profit (12 Mos) | -$71.9M |
Diluted EPS | -$1.58 |
News
See moreYahoo Finance • 12 days ago
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Yahoo Finance • last month
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Yahoo Finance • 2 months ago
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Yahoo Finance • 2 months ago
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
About
CEO | Mr. Adrian H. B. Gottschalk |
Address | 500 Technology Square, Cambridge, MA, United States, 02139 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 112 |
